Table 2.

Core data, characterizing outcome of neoadjuvant chemoradiation and surgery, vs upfront surgery plus adjuvant chemotherapy in patients with resectable and/or borderline resectable pancreatic tumor

Ref.	Patients included	Inclusion periode	Treatment algorithm	Proportion not resected	R0 status	Frequency of vascular resection	Median survival in months
Katz et al[63] 2008	160	1999-2006	Neo-adjuvant	59%	94%	27%	40
Nordby et al[84] 2013	135	2008-2010	Upfront surgery+ adjuvance	11%	42%	6%	Na1
Neop-tolemos et al[76] 2010	1088	2000-2007	Upfront surgery+ adjuvance	Only resected patients included	65%	17%	23
Schmidt et al[77] 2012	132	2004-2007	Upfront surgery+ adjuvance	Only resected patients included	61%	Na2	28

Na1: Too short follow up; Na2: Not given in the paper.